<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03523975</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2018.005</org_study_id>
    <secondary_id>HUM00140979</secondary_id>
    <nct_id>NCT03523975</nct_id>
  </id_info>
  <brief_title>Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma</brief_title>
  <official_title>Phase I Multi-site Study Evaluating the MTD, Safety and Efficacy of the Combination Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Rogel Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan Rogel Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if giving an experimental drug called venetoclax in
      combination with lenalidomide and rituximab is safe and effective for treating people with
      Mantle Cell Lymphoma (MCL).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2018</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of the combination of lenalidomide, venetoclax and rituximab</measure>
    <time_frame>42 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with a Complete Response (CR)</measure>
    <time_frame>Up to 4 Years</time_frame>
    <description>Response will be assessed by the IRC (Immune-related Response Criteria) and the investigator on the basis of physical examinations and PET and CT scans using the Lugano 2014 criteria, taking into account results of bone marrow examinations for patients with bone marrow involvement at screening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients that respond to treatment</measure>
    <time_frame>Up to 4 Years</time_frame>
    <description>The proportion of patients who achieve either partial or complete response by PET, CT and marrow. Response will be assessed by the IRC and the investigator on the basis of physical examinations and PET and CT scans using the Lugano 2014 criteria, taking into account results of bone marrow examinations for patients with bone marrow involvement at screening</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Venetoclax, Lenalidomide, Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab 375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12 Lenalidomide 10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12. Venetoclax PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.</description>
    <arm_group_label>Venetoclax, Lenalidomide, Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12.</description>
    <arm_group_label>Venetoclax, Lenalidomide, Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12</description>
    <arm_group_label>Venetoclax, Lenalidomide, Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Diagnosis of mantle cell lymphoma (MCL) established by histologic assessment

          -  Laboratory, radiographic, physical exam findings and/or symptoms attributable to MCL

          -  ECOG Performance Status (Eastern Cooperative Oncology Group Performance Status: an
             attempt to quantify cancer patients' general well-being and activities of daily life.
             The score ranges from 0 to 5 where 0 is asymptomatic and 5 is death) less or equal to
             2

          -  All study participants must be registered into the mandatory Revlimid REMS® program,
             and be willing and able to comply with the requirements of the REMS® program

          -  Females of reproductive potential must adhere to the scheduled pregnancy testing as
             required in the Revlimid REMS® program.

          -  Men and Women of childbearing potential on appropriate contraception

          -  Adequate organ function

          -  Ability to understand and the willingness to sign a written informed consent.

          -  Ability to swallow oral capsules/tablets

        Exclusion Criteria:

          -  Prior treatment for MCL with chemotherapy

          -  Pregnant or breastfeeding women

          -  Grade 2 or higher peripheral neuropathy

          -  Known history of CNS (Central Nervous System) or leptomeningeal by MCL prior to study
             enrollment

          -  Significant cardiovascular disease

          -  Any condition that might significantly impair drug absorption as determined by the
             investigator

          -  Uncontrolled active systemic fungal, bacterial, viral, or other infection, or
             intravenous anti-infective treatment within 2 weeks before first dose of study drug

          -  History of stroke or intracranial hemorrhage within 6 months of 1st dose of study drug

          -  Concurrent participation in another clinical trial

          -  Subject has received a moderate or strong CYP3A inhibitor or inducer within 1 week
             prior to treatment initiation.

          -  Psychiatric illness or social situations that would limit compliance with study
             requirements

          -  Subject has known positivity to HIV

          -  Active infection with Hepatitis B or C virus as determined by a detectable viral load
             on PCR.

          -  Prior malignancy except for adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer, or any other cancer from which the subject has been
             disease free for ≥ 2 years or which will not limit survival to&lt; 2 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tycel Phillips, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cancer AnswerLine</last_name>
    <phone>1-800-865-1125</phone>
    <email>CancerAnswerLine@med.umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Popplewell, MD</last_name>
      <phone>626-256-4673</phone>
      <email>lpopplew@coh.org</email>
    </contact>
    <investigator>
      <last_name>Leslie Popplewell, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michgan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48187</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tycel Phillips, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ohio State Comprehensive Cancer Center</last_name>
      <phone>800-293-5066</phone>
      <email>OSUCCCClinicaltrials@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kami Maddocks, MD</last_name>
      <email>Kami.Maddocks@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kami Maddocks, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 26, 2018</study_first_submitted>
  <study_first_submitted_qc>May 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2018</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

